uniQure N.V. (QURE) AI Stock Summary

Snapshot

QURE is a clinical-stage gene therapy company that is currently unprofitable and shrinking. FY 2025 revenue dropped 41% to $16.1M while the company spent $141M on R&D, resulting in a $199M net loss. It holds $622.5M in cash against $536.6M in debt. The calculated cash runway is tight at 6.9 months, which conflicts with the company's recent statement that it has funding into the second half of 2029. A cluster of nine officers and directors sold shares in June, signaling caution from insiders.

What's Happening Right Now

• Wed 17th Jun '26 · Regulatory Update: uniQure announced plans to submit a Biologics License Application for AMT-130 in Huntington's disease in Q3 2026 after the FDA agreed that 3-year analysis data can serve as the basis for accelerated approval.
• Tue 5th May '26 · Earnings: Q1 2026 revenue was $3.6M with a net loss of $53.5M. The company stated it has a cash runway into the second half of 2029, despite prior FDA feedback requiring a new clinical trial design for AMT-130.

Ownership

Institutions hold 98.9%, insiders hold 2.6%.

Bottom Line

The stock is currently a binary bet on the regulatory path for AMT-130. The positive FDA news in June is a major catalyst, but the underlying business is burning cash faster than it generates revenue. Investors must decide if the regulatory progress justifies the high burn rate and insider selling pressure.